GlassScriptPhysician profile
Matthew G Sweetser
NPI 1679594170
$221.61
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $17.63 · 2021: $37.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38.28 | 2019 | |
| Celgene Corporation | $30.56 | 2019 | |
| Eisai INC. | $18.88 | 2019 | |
| Genentech USA, INC. | $17.66 | 2019 | |
| Amgen INC. | $17.63 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.40 | 2019 | |
| Incyte Corporation | $16.00 | 2019 | |
| Emd Serono, INC. | $15.00 | 2019 | |
| Pfizer INC. | $13.86 | 2021 | |
| Janssen Biotech, INC. | $13.45 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Sweetser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.